Investment Management of Virginia’s Alexion Pharmaceuticals ALXN Stock Holding History

Investment Management of Virginia’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,902	Closed	-$979K	–	146
2020 Q1	$979K	Sell	10,902 -185	-2%	-$18.2K	0.3%	94
2019 Q4	$1.2M	Buy	11,087 +2,380	+27%	+$255K	0.27%	85
2019 Q3	$853K	Buy	8,707 +345	+4%	+$38.9K	0.21%	100
2019 Q2	$1.09M	Sell	8,362 -8,442	-50%	-$1.09M	0.26%	100
2019 Q1	$2.27M	Buy	16,804 +11,412	+212%	+$1.42M	0.27%	101
2018 Q4	$525K	Sell	5,392 -3,013	-36%	-$356K	0.14%	127
2018 Q3	$1.17M	Sell	8,405 -720	-8%	-$90.3K	0.25%	101
2018 Q2	$1.13M	Buy	9,125 +3,895	+74%	+$455K	0.25%	106
2018 Q1	$583K	Buy	5,230 +480	+10%	+$57.4K	0.14%	126
2017 Q4	$568K	Sell	4,750 -10	-0.2%	-$1.22K	0.13%	124
2017 Q3	$668K	Buy	+4,760	New	+$647K	0.16%	120

Other funds holding ALXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Investment Management of Virginia's ALXN Position: Q2 2020 in Review

Investment Management of Virginia sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 10,902 shares — an estimated $979K sold.

Investment Management of Virginia first reported a position in ALXN in Q3 2017 and held it in 11 quarters. The position peaked at $2.27M in Q1 2019. 706 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

Investment Management of Virginia reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Investment Management of Virginia sold 10,902 Alexion Pharmaceuticals shares in Q2 2020, an estimated $979K.
Investment Management of Virginia first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 11 quarters.
Investment Management of Virginia's Alexion Pharmaceuticals position peaked at $2.27M in Q1 2019.
706 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Investment Management of Virginia's 13F filing for Q2 2020, filed 11 Aug 2020.